# Chronic Stress Induces Hepatic Steatosis via Brain-Hepatic Sympathetic Axis Mediated Catecholamine Resistance

**Authors:** Shanshan Wu, Jiachen Liu, Shanshan Huang, Yuxin Guo, Yan Bi

PMC · DOI: 10.7150/ijbs.126058 · International Journal of Biological Sciences · 2026-01-08

## TL;DR

Chronic stress causes liver fat buildup through a brain-liver nerve pathway that reduces liver sensitivity to stress hormones.

## Contribution

The study identifies a novel brain-liver sympathetic pathway linking chronic stress to liver disease.

## Key findings

- Chronic stress in mice causes liver fat accumulation independent of weight gain.
- Stress reduces liver sensitivity to norepinephrine via downregulation of β3-adrenergic receptors.
- Blocking sympathetic nerve input or activating β3-AR prevents stress-induced liver fat buildup.

## Abstract

Chronic stress is epidemiologically linked to metabolic dysfunction-associated steatotic liver disease (MASLD), yet the underlying mechanisms remain unclear. In mice exposed to chronic restraint stress (CRS), we observed weight-independent hepatic steatosis with marked degeneration of sympathetic fibers. Stress elevated circulating norepinephrine levels but blunted hepatic β-adrenergic/cyclic adenosine monophosphate (cAMP) signaling accompanied by downregulation of β3-adrenergic receptor (β3-AR), indicating hepatic catecholamine resistance. Blocking hepatic sympathetic input prevented stress-aggravated steatosis and restored β-adrenergic signaling, whereas pharmacologic activation of β3-AR with mirabegron alleviated stress-induced lipid accumulation. Pseudorabies virus retrograde tracing and neuronal circuit interrogation further showed that projection from the medial central amygdaloid nucleus (CeM) to paraventricular hypothalamic corticotropin-releasing hormone (CRHPVH) neurons mediated stress induced hepatic steatosis. Together, these results reveal a CeM-CRHPVH-hepatic sympathetic axis that couples central stress signaling to peripheral β-adrenergic desensitization and lipid dysregulation, thereby suggesting a potential therapeutic strategy for stress-related MASLD.

## Linked entities

- **Chemicals:** norepinephrine (PubChem CID 951), mirabegron (PubChem CID 9865528)
- **Diseases:** metabolic dysfunction-associated steatotic liver disease (MONDO:0013209)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, ADRB3 (adrenoceptor beta 3) [NCBI Gene 155] {aka BETA3AR}
- **Diseases:** metabolic dysfunction (MESH:D008659), Hepatic Steatosis (MESH:D005234), MASLD (MESH:D008107), catecholamine (MESH:C536334)
- **Chemicals:** norepinephrine (MESH:D009638), mirabegron (MESH:C520025), cyclic adenosine monophosphate (MESH:D000242), Catecholamine (MESH:D002395), cAMP (-), lipid (MESH:D008055)
- **Species:** Suid alphaherpesvirus 1 (no rank) [taxon 10345], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12837740/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12837740/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12837740/full.md

---
Source: https://tomesphere.com/paper/PMC12837740